Adma Biologics Inc (NASDAQ:ADMA) has a beta value of 0.72 and has seen 0.49 million shares traded in the recent trading session. The company, currently valued at $5.06B, closed the recent trade at $21.42 per share which meant it lost -$0.05 on the day or -0.21% during that session. The ADMA stock price is -10.36% off its 52-week high price of $23.64 and 83.19% above the 52-week low of $3.60. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.82 million shares traded. The 3-month trading volume is 5.11 million shares.
The consensus among analysts is that Adma Biologics Inc (ADMA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.16.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ:ADMA) trade information
Sporting -0.21% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADMA stock price touched $21.42 or saw a rise of 2.1%. Year-to-date, Adma Biologics Inc shares have moved 374.00%, while the 5-day performance has seen it change 3.85%. Over the past 30 days, the shares of Adma Biologics Inc (NASDAQ:ADMA) have changed 30.40%. Short interest in the company has seen 15.2 million shares shorted with days to cover at 3.53.
Wall Street analysts have a consensus price target for the stock at $16, which means that the shares’ value could drop -33.88% from the levels at last check today. The projected low price target is $14.0 while the price target rests at a high of $18.0. In that case, then, we find that the latest price level in today’s session is 15.97% off the targeted high while a plunge would see the stock lose 34.64% from the levels at last check today.
Adma Biologics Inc (ADMA) estimates and forecasts
The company’s shares have gained 127.93% over the past 6 months, compared to 17.90% for the industry. Revenue growth from the last financial year stood is estimated to be 63.57%.
4 analysts offering their estimates for the company have set an average revenue estimate of 113.4M for the current quarter. 4 have an estimated revenue figure of 112.9M for the next ending quarter. Year-ago sales stood 73.9M and 81.88M respectively for this quarter and the next, and analysts expect sales will grow by 53.44% for the current quarter and 63.57% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 38.68% over the past 5 years. Earnings growth for 2024 is a modest 494.23% while over the next 5 years, the company’s earnings are expected to increase by 20.00%.
ADMA Dividends
Adma Biologics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders own 2.51% of the company shares, while shares held by institutions stand at 90.92% with a share float percentage of 93.26%. Investors are also buoyed by the number of investors in a company, with Adma Biologics Inc having a total of 408.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 18.64 million shares worth more than $208.45 million. As of 2024-06-30, BLACKROCK INC. held 8.1462% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 14.52 million shares as of 2024-06-30. The firm’s total holdings are worth over $162.3 million and represent 6.3426% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 6.26% shares in the company for having 14.8 shares of worth $317.24 million while later fund manager owns 6.74 shares of worth $144.58 million as of Jun 30, 2024, which makes it owner of about 2.85% of company’s outstanding stock.
